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ABSTRACT
PREDICTORS OF ADULT OUTCOME OF PEDIATRIC-ONSET OBSESSIVECOMPULSIVE DISORDER. Brittany G. Craiglow, Michael H. Bloch, Angeli LanderosWeisenberger, Philip A. Dombrowski, Kaitlyn E. Panza, Bradley S. Peterson, and James
F. Leckman. Child Study Center, Yale University School of Medicine, New Haven, CT.

This study was conducted in order to determine childhood clinical predictors of early
adult outcome in pediatric-onset obsessive-compulsive disorder (OCD). We specifically
hypothesized that OCD symptom dimensions and comorbid tic disorders would be
associated with persistence of obsessive-compulsive (OC) symptoms into early
adulthood. The study followed a longitudinal cohort design in which 45 of 61 eligible
children with OCD were reassessed in early adulthood an average of 9 years following a
baseline childhood assessment. Main outcome measures included expert-rated OC
symptom severity and time to remission of OC symptoms. Baseline clinical
characteristics were evaluated in terms of their impact on early adulthood OC symptom
severity and time to remission of OC symptoms.
Forty-four percent of subjects were determined to have subclinical OC symptoms
at follow-up. Absence of a comorbid tic disorder and presence of prominent hoarding
symptoms were associated with OC symptom persistence. In our best-fitting multivariate
Cox Proportional Hazard model female gender, younger age at childhood baseline
assessment, older age of OCD onset, more severe childhood OC symptoms, and
comorbid oppositional defiant disorder were also independently associated with
persistence of OC symptoms into early adulthood. Our results suggest that a significant
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proportion of patients with pediatric-onset OCD will remit by early adulthood. The
presence of comorbid tics was associated with a favorable outcome, while primary
hoarding symptoms were associated with persistent OCD.
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INTRODUCTION
Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder (OCD) is a neuropsychiatric condition characterized by
intrusive thoughts or images (obsessions) and/or repetitive behaviors or mental rituals
(compulsions) that are often aimed at preventing or alleviating anxiety generated by
obsessions. Common obsessions include fears of causing harm to oneself or others, fears
of contamination, and need for symmetry and exactness, while common compulsions
include behaviors such as cleaning, ordering, or checking, and mental rituals such as
counting or repeating words silently (1). To meet diagnostic criteria for OCD, a person’s
symptoms must not be due to a general medical disorder or substance, and he or she must
experience recurrent obsessions or compulsions that are severe enough to be timeconsuming or cause significant distress or impairment. In addition, the DSM criteria
specify that for adults with OCD, at some point the person must recognize that his or her
symptoms are excessive or unreasonable; in children, this criterion is often not met (2).
Obsessions and compulsions can be significantly disruptive to overall functioning,
as they can take the place of productive and enjoyable behaviors. Many individuals with
OCD avoid certain situations or objects that stimulate obsessions or compulsions, and
such avoidance can become widespread and generalized. Additionally, because
obsessions can be distracting, they may interfere with performance on certain cognitive
tasks, such as reading or computation (2). Studies of OCD in children and adolescents
have consistently reported substantial interference of symptoms with social, scholastic,
and psychosocial functioning (3).
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Epidemiology
The symptoms of OCD are similar across many cultures (4), and OCD affects an
estimated 50 million people worldwide (5). In the United States the lifetime prevalence
of OCD was found to be between 1.9% and 3.3% based on the Epidemiological
Catchment Area study, which examined a representative sample of 18,500 people from
five geographical areas (6). These results suggested that OCD is the fourth most
common psychiatric disorder, following phobias, substance abuse, and major depression.
In a cross-national study using similar methodology, lifetime prevalence was found to be
remarkably consistent among seven countries: the United States, Canada, Puerto Rico,
Germany, Taiwan, Korea, and New Zealand. The OCD annual prevalence ranged from
1.1/100 in Korea and New Zealand to 1.8/100 in Puerto Rico. The population of Taiwan,
which has the lowest prevalence for other psychiatric disorders, was the least affected,
with a prevalence of OCD of 0.4/100 (4).
More recently, an evaluation of OCD was included in the National Comorbidity
Survey Replication (NCS-R), which is the most current large-scale epidemiological
survey of the United States population to date. While the earlier NCS did not include
OCD, the NCS-R assessed both lifetime experiences of OCD as well as nine types of
common obsessions and compulsions, and also provided information regarding
comorbidity, impairment, and treatment (7). Lifetime and 12-month prevalence estimates
from this study were 2.3% and 1.2%, respectively. Although OCD is defined by
obsessive-compulsive (OC) symptoms severe enough to be time consuming or cause
significant distress or impairment (2), a wide range of less severe OC symptoms is
common among the general and non-referred population. In the NCS-R, over one-quarter
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of respondents (28.2%) reported experiencing obsessions or compulsions at some point in
their lives, most commonly checking, hoarding, or ordering (7). Another recent
community-based sample demonstrated similar prevalence rates of obsessions and
compulsions, with 13-17% of patients without a psychiatric diagnosis experiencing
obsessions or compulsions, and 31-49% of individuals with a psychiatric diagnosis other
than OCD experiencing them (8). The cross-national variance in OCD noted above
might in part be related to the relatively high frequency of obsessions and compulsions in
community samples and differences in what is considered to be significantly timeconsuming, impairing, or distressing.
Obsessive-compulsive disorder can be severely impairing and has been named by
the World Health Organization as one of the top 10 causes of worldwide ‘years lived with
illness-related disability’ (9). Nearly two-thirds of individuals with OCD assessed by the
NCS-R reported severe role impairment, particularly within relationship and social
functioning domains, and past-year OCD was associated with an average of 45.7 days out
of role in the past 12 months. Notably, among the group of respondents with severe
OCD, the average number of days out of role was significantly higher at 129.4 (7). Not
surprisingly, the economic burden of OCD is also considerable – for instance, in 1990 the
total cost of OCD in the United States alone was estimated to be upwards of $8.4 billion,
and the indirect cost, which reflects loss of productivity from individuals suffering with
OCD, was estimated at $6.2 billion (10).

Etiology and Pathogenesis
Genetics
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Relatively little is known about the etiology and neurobiological origins of OCD (11).
There is compelling evidence from twin, family, segregation, and linkage studies that
genetic factors play an important role (12). A recent review that examined the literature
of all twin studies for OCD published since 1929 concluded that OC symptoms are
heritable in children, with genetic influences ranging from 45% to 65%. The genetic
influence on OC symptoms in adults ranged from 27% to 47% (13). Results from a
number of family studies of OCD also support the hypothesis that some forms of OCD
are familial (12). A recent meta-analysis of five OCD family studies demonstrated that
the unadjusted aggregate risk for OCD among proband relatives was 8.2%, as compared
with 2.0% for control relatives (14). Segregation analyses, which are used to examine
patterns of inheritance within families, have demonstrated that the pattern of transmission
of OCD is consistent with one of genetic transmission (12).
Upwards of 60 candidate gene studies have been reported in the past decade (15),
with mixed results. Some studies have suggested a genetic association between OCD and
genes in the dopaminergic and serotonergic pathways, while others have failed to
replicate such findings. None to date have reached genome-wide significance, which
may in part be due to the clinical heterogeneity of OCD (12). Genetic linkage studies
have also yielded somewhat varied results, but taken together studies suggest that there
may be a susceptibility locus located on chromosome 9 (12, 16).

Environmental Factors
In addition to genetic factors, environmental influences are likely to be implicated in the
etiology of OCD; however, very little is known about environmental triggers for the
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disorder (17). There is some evidence that traumatic or stressful events may be risk
factors for developing OCD. One study demonstrated that children with OCD had
significantly more total and negative life events in the year prior to onset of OCD than
normal controls, and they also perceived these events as having more impact (18). It has
also been reported that statistically significant covariation between lifetime posttraumatic stress disorder (PTSD) and OCD was attributable to cases in which a principal
diagnosis of PTSD was followed by a secondary diagnosis of OCD (19), suggesting that
precipitants or features of PTSD may act as causal factors in OCD (17).
Another study found that the only difference between patients with familial and
non-familial OCD was that life events prior to the onset of OCD were more common and
more severe in patients with non-familial OCD (20). Pregnancy and childbirth have also
been associated with precipitation or exacerbation of OCD (21). Finally, the results of
the NCS-R demonstrated that in adults OCD typically emerges following the onset of
other psychiatric disorders and begins at a later age than most (79.6%) comorbid anxiety
disorders. Earlier mental disorders predict the subsequent first onset of OCD, with the
highest odds of subsequent OCD associated with preexisting bipolar disorder,
agoraphobia, panic disorder, and alcohol dependence (7).

Neuroanatomy
The current dominant model of OCD suggests that the disorder is mediated by specific
neuronal circuits, with emphasis on abnormalities in cortico-striatal circuitry, in particular
orbitofronto-striato-thalamic circuits (16). Three neuroanatomical areas have been
consistently implicated in a variety of types of neuroimaging studies of OCD – the
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orbitofrontal cortex, the anterior cingulate cortex, and the head of the caudate nucleus
(22). These areas are hyperactive at rest in adults with OCD as compared to healthy
controls, become more active with provocation of symptoms, and are no longer
hyperactive at rest following successful treatment with either pharmacological treatment
or cognitive-behavioral therapy (22). Recent studies suggest the existence of other
structural abnormalities in OCD, particularly within the parietal cortex (23, 24),
generating evidence for a revised model for OCD in which the underlying pathology
involves abnormalities in lateral and frontal parietal regions in addition to orbitofrontostriatal regions and their associated limbic structures (16).

Neurochemistry
The evidence that serotonin reuptake inhibitors are effective in the treatment of OCD led
to the development of the serotonergic hypothesis (25), which although plausible has not
been proven conclusively (26). The hypothesis suggests that there is an abnormality in
the serotonergic system in OCD, presumably related to a reduction of function (26). The
results from pharmacological, genetic, and imaging studies lend support for a role for
serotonin in OCD, but to date no specific abnormality has been identified within the
serotonin system (27). While it appears that serotonin does play some part in the
disorder, its role may be secondary and modulatory rather than primary (26).
There is now growing evidence that the dopamine system may also be involved in
the pathogenesis of OCD (28). The results of most studies that have examined the role of
dopamine in OCD suggest an association between increased midbrain dopamine
neurotransmission and the disorder (29), a hypothesis which is in agreement with the
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hyperactive cortico-striatal-thalamic model of OCD (28). Finally, there is evidence that
dysregulation of glutamate neurotransmission may also contribute to the pathophysiology
of OCD, and preliminary studies of glutamate-modulating drugs such as riluzole, an
antiglutamatergic agent, have achieved promising results in the treatment of OCD (30).

Neuroimmunology
There is a growing body of evidence to suggest that immune mechanisms may play a role
in the pathophysiology of some subtypes of OCD (31). In particular, it has been
hypothesized that some individuals develop OCD following infection with group-A betahemolytic streptococcal infections. The acronym ‘PANDAS’ (Pediatric Autoimmune
Neuropsychiatric Disorders Associated with Streptococcal Infections) has been coined to
describe patients who meet five inclusionary criteria: presence of OCD and/or tic
disorder, pre-pubertal symptom onset, sudden onset or episodic course of symptoms,
temporal association between streptococcal infections and neuropsychiatric symptom
exacerbations, and associated neurological abnormalities (32). This putative subgroup of
patients experiences a unique clinical course in which the onset of symptoms tends to be
abrupt and dramatic, and which is temporally linked with streptococcal infections. Some
patients with PANDAS have been shown to benefit from immunomodulatory therapies
and long-term antibiotic therapy (33). In addition, children with PANDAS during the
acute phase of illness have been shown to have larger caudate, putamen, and globus
pallidus volumes when compared to healthy controls (34).
Perhaps the strongest evidence to support the notion that streptococcal infection
may be related to the onset of OCD comes from a case-control study of 144 patients
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reported by Mell and colleagues (35) who demonstrated that patients with OCD, Tourette
Syndrome (TS), or tic disorder were significantly more likely than controls to have had
prior streptococcal infection in the 3 months prior to onset. The risk was even higher
among children with multiple streptococcal infections within 12 months of onset. Similar
results were recently reported based on a national sample of OCD cases (36). Further
research will be necessary to clarify the relationship between immune mechanisms and
OCD; the results of current studies that are investigating the specific antineuronal
antigens and antibodies that characterize members of the PANDAS subgroup will likely
be of particular interest (31).

Comorbidity
Rates of comorbid psychiatric illness are high among individuals with OCD. In the NCSR, fully 90% of respondents with OCD met criteria for another lifetime DSM-IV
disorder. The most common comorbid conditions were anxiety disorders (75.8%),
followed by mood disorders (63.3%), impulse-control disorders (55.9%), and substance
use disorders (38.6%) (7). Comorbid psychopathology is also extremely common among
children and adolescents with OCD – in one study of pediatric patients, only one
participant out of 30 failed to meet criteria for at least one psychiatric diagnosis other
than OCD (37). Rates of comorbid lifetime major depression are higher in adults (78%)
than in adolescents (62%) or children (39%), whereas Tourette Syndrome is more
prevalent among children with OCD (25%) than among adolescents (9%) or adults (6%)
with OCD (38). While disruptive behavior disorders are not typically reported in adult
populations, they frequently co-occur in children and adolescents with OCD. Rates of
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attention deficit hyperactivity disorder have been reported at 51% among children and
36% among adolescents, and rates of oppositional defiant disorder are 51% and 47%
among children and adolescents, respectively (38).

Treatment
Psychotherapy
Controlled clinical trials have consistently demonstrated that psychotherapeutic
interventions for OCD, including exposure response prevention (ERP) and cognitive
therapy, substantially reduce obsessive-compulsive symptomatology. ERP is based on
the notion that classical conditioning is responsible for the development of obsessions,
while operant conditioning perpetuates anxiety and maintenance behaviors, and therefore
it consists of both exposure to the anxiety-provoking obsessions as well as prevention of
responses aimed at reducing anxiety (39). In ERP patients create a hierarchy of feared
situations that trigger anxiety and/or obsessions, and then sequentially move up the
hierarchy following successful habituation to each OCD trigger. Importantly, effective
ERP necessitates that each exposure be followed by response prevention, in which the
patient neither avoids the trigger nor performs rituals to alleviate anxiety (40). Cognitive
therapy is based on the cognitive theory of emotional disorders and attempts to modify
dysfunctional beliefs or faulty appraisals of stimuli that generate obsessions (39, 40).
A recent meta-analysis that examined the results of 15 clinical trials of
psychological therapy for OCD demonstrated that across all treatments about two-thirds
of patients who completed treatment improved (range: 33–78%), and one-third met
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recovery criteria (range: 27–47%). Findings were strongest for more behaviorallyoriented treatments, such as ERP, and for individual as opposed to group therapy (39).

Pharmacotherapy
While OCD is certainly influenced by learning principles, it is also a biologically-based
disorder and consequently medication is an important component of treatment (40).
Meta-analyses and reviews of pharmacologic treatment for OCD have consistently
supported the use of antidepressants (41). In particular, evidence from randomized
controlled trials shows that serotonin reuptake inhibitors (SRIs) are effective in OCD.
SRIs include both non-selective serotonin reuptake inhibitors such as clomipramine, as
well as selective serotonin reuptake inhibitors (SSRIs), such as citalopram, fluoxetine,
fluvoxamine, paroxetine, and sertraline. A recent Cochrane review of SSRIs in the
treatment of OCD demonstrated that patients receiving SSRIs were nearly twice as likely
as those receiving placebo to achieve clinical response, which was defined as a 25% or
greater reduction in symptoms (26). Another meta-analysis of studies of the efficacy of
both selective and non-selective serotonin reuptake inhibitors as well as tricyclic
antidepressants demonstrated greatest effect sizes for clomipramine, suggesting that this
nonspecific SRI may be more effective than SSRIs and tricyclics in targeting obsessivecompulsive symptoms. It is worth noting, however, that the largest effect sizes for
clomipramine were found in early studies and have not been as clearly replicated in more
recent studies comparing it with SSRIs. Furthermore, clomipramine tends to have a less
favorable side effect profile than the SSRIs, causing many patients to stop taking it
despite its positive effects (41). Recent reports indicate that children and adolescents
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with OCD and comorbid tics are less likely to respond well to SSRIs (42).
For patients who do not respond to SRIs, several studies have demonstrated that
augmentation with antipsychotic medication can be effective in some cases. In a recent
meta-analysis of such studies it was found that approximately one-third of patients with
treatment-refractory OCD show a meaningful treatment response to antipsychotic
augmentation. The report suggests that there is sufficient evidence demonstrating the
efficacy of haloperidol and risperidone but states that evidence regarding the efficacy of
quetiapine and olanzapine is inconclusive (43). A Cochrane review on the same subject
concluded that antipsychotic augmentation can be an effective and well-tolerated shortterm treatment strategy for patients who do not respond to first-line pharmacotherapy for
OCD (44). The results of such studies, along with the more favorable side effect profiles
of newer generations of antipsychotics, are contributing to a growing consensus that
antipsychotics are the pharmacotherapy augmentation of choice in SRI-refractory OCD
(45). This appears to be particularly the case for patients with OCD and a personal
history of tics (43).

Combined Treatment
Because neither psychological therapy nor pharmacotherapy alone has been effective for
all patients with OCD, a combination is often recommended as treatment of choice (40).
In fact, effect sizes for combined psychotherapy and pharmacotherapy have been shown
to be higher than those for either treatment modality alone (41). In a meta-analysis of
pharmacotherapy trials in OCD among children and adolescents Geller and colleagues
(46) found that medications were significantly more effective than placebo, with an effect
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size of 0.46. The Pediatric OCD Treatment Study (POTS) (47) compared sertraline,
cognitive-behavioral therapy (CBT), combined sertraline and CBT, and placebo for the
treatment of OCD. The clinical remission rate for combined treatment was 53.6%; for
CBT alone 39.3%; for sertraline alone 21.4%; and for placebo 3.6%, leading the authors
to recommend that children and adolescents with OCD should begin treatment with either
CBT or the combination of CBT and medication.

OCD Symptom Dimensions
Obsessive-compulsive disorder is heterogeneous in its clinical presentation, with many
possible subtypes (48, 49). It is not unusual for two patients with OCD to display
completely different symptom patterns (50). Despite this variability, OCD continues to
be regarded by standard diagnostic classifications such as the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV-TR) (2) and the International Classification of
Diseases, Tenth Edition (51) as a unitary nosological entity (50). While experts
acknowledge that this characterization has certain formal appeal, it also has the potential
to be misleading (50). The psychiatric community has recognized this, and a majority of
OCD experts worldwide agree that “OCD is heterogeneous, that symptoms are
experienced with multiple potentially overlapping symptom dimensions, and that it will
be important to document their presence as specifiers in the DSM-V” (52). As
investigators have sought to understand and describe the heterogeneity of OCD, a
growing body of evidence has emerged in favor of a multidimensional model of the
disorder.
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The multidimensional approach is based on the notion that the complex clinical
presentation of OCD can be summarized with a few consistent, temporally stable clusters
of symptoms, referred to as symptom dimensions or factors (50). Over 20 factor analytic
studies conducted on large cohorts of patients with OCD have identified potential
symptom dimensions (53). In addition, these OCD symptom dimensions have been
associated with distinct patterns of comorbid psychiatric conditions (54), different
patterns of heritability (55), and different responses to pharmacological treatment and
behavioral therapy (56, 57). In particular, a number of studies have demonstrated that
patients with prominent hoarding symptoms respond more poorly to SSRIs (56, 58, 59)
and have poor compliance with and response to cognitive-behavioral therapy (60, 61).
The results of these and similar studies suggest that adopting a multidimensional
approach to OCD has the potential to broaden understanding of the disorder (62).
A recent study synthesized data from 21 factor analytic studies involving over
5,000 subjects and via stratified meta-analysis demonstrated a four-factor structure for
OCD that was remarkably consistent over time (53). The four OCD factors that emerged
were: Factor I/Forbidden Thoughts, consisting of aggression, sexual, religious, and
somatic obsessions and checking compulsions; Factor II/Symmetry, consisting of
symmetry obsessions and ordering, repeating, and counting compulsions; Factor
III/Cleaning, consisting of contamination obsessions and cleaning compulsions; and
Factor IV/Hoarding, consisting of hoarding obsessions and compulsions. A similar fourfactor structure has been demonstrated by a confirmatory factor analysis of children,
adolescents, and adults with OCD (63). Importantly, the results of a recent study that
examined the structure of obsessive-compulsive (OC) symptoms in a large pediatric
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sample also demonstrated that symptom dimensions are similar across the lifespan (62),
indicating that the factor structure may be applied to both pediatric- and adult-onset
OCD.

Tic-Related OCD
A dimensional approach does not exclude other methods of sub-classifying OCD.
Currently tic-related OCD, familial OCD, and pediatric-onset OCD appear to be
potentially useful categorical distinctions (38, 64). Perhaps the best-described subgroup
is tic-related OCD, which has been defined as a condition in which tics are observed
either in the patient or in at least one first-degree relative (64). Patients with tic-related
OCD have an earlier age of onset (49, 65, 66) and are more frequently males (48, 65). In
addition, patients with tic-related OCD tend to display symptoms within the Forbidden
Thoughts, Symmetry, and Hoarding dimensions more often than symptoms within the
Cleaning dimension (67-69). Similarly, tic-related OCD has been associated with higher
frequencies of sensory phenomena that precede or accompany compulsions (48, 69, 70).
Some studies have reported that patients with tic-related OCD have higher rates of
comorbid trichotillomania, body dysmorphic disorder, social phobia, mood disorders, and
attention-deficit hyperactivity disorder when compared with patients with non-tic-related
OCD (71, 72). The results of longitudinal studies have also demonstrated that the
presence of comorbid tics may be associated with increased OCD severity (73, 74).
Finally, patients with tic-related OCD may not respond as favorably to treatment with
SSRIs when compared to patients with non-tic-related OCD (38, 47), and as noted above,
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individuals with tic-related OCD are also more likely to benefit from augmentation with
antipsychotic medication (43).

Pediatric-Onset OCD
Obsessive-compulsive disorder was previously thought to be very rare among pediatric
populations; however, over the past two decades research has emerged identifying OCD
as one of the more common psychiatric illnesses affecting children and adolescents (75).
Epidemiological studies have documented roughly equivalent prevalence rates for
pediatric and adult OCD (6, 76-78), and studies of children and adolescents with OCD
have reported similarities with adult OCD (79). Importantly, however, several
meaningful differences between pediatric- and adult-onset OCD have been identified,
causing pediatric-onset OCD (including children and adolescents with OCD as well as
adults with an early onset of symptoms) to be hypothesized to represent a distinct
developmental subtype of OCD (66, 79).
Perhaps the most apparent distinction between pediatric- and adult-onset OCD
relates to age of onset data, which demonstrates a bimodal distribution with one peak in
childhood and another in adulthood (79). Pediatric-onset OCD has been associated with
a mean age of onset around 10 years (79) in contrast to adult-onset OCD, which has been
reported to have a mean age of onset of around 21 years (6, 80). In some studies
pediatric-onset OCD has also been associated with a male preponderance (79), as
compared to adult studies of OCD that have demonstrated slight female predominance or
equal gender distribution (6). In addition, pediatric-onset OCD has been associated with
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a higher rate of comorbid tic disorders (81), greater familial loading for OCD as
demonstrated by family studies (9, 82), and poorer response to medications (66).

Course and Long-term Outcome of Pediatric-Onset OCD
Earlier studies of pediatric-onset OCD indicated that the disorder typically follows an
unremitting, debilitating course (76, 83-85), a notion that has been perpetuated by clinical
lore (75). This idea is also upheld by the DSM-IV-TR, which states that OCD follows a
chronic course in the majority of individuals (2). Recent data calls these teachings into
question, however, and as a result a shift in the understanding of the course and long-term
outcome of pediatric-onset OCD has begun to occur (75).
The prevalence of OCD among adults is relatively equivalent to that among
children and adolescents (6, 76, 78), and given that a significant portion of cases of OCD
develop following adolescence, the similar prevalence rates in these two age groups
suggests that many cases of pediatric-onset OCD remit prior to adulthood. Indeed, the
results of a recent review and meta-analysis of previous long-term outcome studies of
pediatric-onset OCD support this premise, suggesting that as many as 40-59% of cases
remit by adulthood (75). This first systematic review of pediatric-onset OCD
demonstrated that rates of persistence are lower than previously believed and outlined in
the DSM-IV, with two-thirds of studies analyzed demonstrating that OCD did not persist
as a full syndrome into adulthood for a majority of patients.
In addition to examining rates of persistence, this review examined predictors of
outcome of pediatric-onset OCD. Meta-analysis regression demonstrated that earlier age
of OCD onset, longer duration of OCD prior to treatment, and inpatient hospitalization
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for OCD were predictive of OCD persistence (75). Selected longitudinal studies have
reported presence of a comorbid tic (73, 74) or mood disorder (73), family psychiatric
history, and poor initial response to pharmacologic treatment (73) as additional predictors
of greater OCD severity at follow-up.
Many of the studies that have examined long-term outcome of pediatric-onset
OCD were conducted prior to the widespread use of effective evidence-based treatments
for OCD, such as SSRIs and cognitive-behavioral therapy, and before the introduction of
validated clinical rating scales for OCD, suggesting that many of them may no longer be
applicable to current patients. In addition, most of these studies had follow-up intervals
that ranged from only 1-5 years and thus had a limited ability to assess adult outcome, or
they were retrospective in character and therefore prone to recall bias (75). For these
reasons, further investigation into the early adult outcome of pediatric-onset OCD is
warranted.

Current Study
In light of the limitations of previous longitudinal studies examining outcome of
pediatric-onset OCD and the emerging body of evidence in support of a multidimensional
model of OCD, we conducted this prospective, longitudinal study in order to evaluate the
course and early adult outcome of pediatric-onset OCD. Given the prevalence,
morbidity, and functional impairment associated with OCD, a better understanding of its
progression is important and will undoubtedly be helpful for clinicians and patients alike
(75). The goals of this current study were to (1) determine childhood clinical predictors
of early adult outcome in pediatric-onset OCD and (2) determine whether specific OCD
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symptom dimensions are associated with outcome of pediatric-onset OCD as assessed in
early adulthood. We hypothesized that OCD symptom dimensions and comorbid tic
disorders would be associated with persistence of OC symptoms into early adulthood.
The first hypothesis was generated in large part because of the results of prior
studies that have suggested that a dimensional approach may prove to be a valuable
means for identifying predictors of outcome (86). As noted above, patients with hoarding
symptoms have been shown to respond less favorably to both SSRIs (56, 58, 59) and
cognitive-behavioral therapy (60, 61). Other studies have demonstrated that the presence
of other symptoms, especially sexual obsessions, may predict non-response to SSRIs (87,
88). These data suggest that there may be fundamental differences among symptom
dimensions in terms of the clinical course and outcome of OCD, and we speculated that
we would identify one or more symptom dimensions that carried with it a poorer
prognosis. The hypothesis that patients with OCD and tics would have a less favorable
outcome was based on the results of selected longitudinal studies that have reported that
the presence of a comorbid tic disorder may predict worse long-term outcome (73, 74)
and poorer response to treatment with SSRIs (38, 47).

PATIENTS AND METHODS
Participants
All participants were recruited through the Yale Tourette Syndrome (TS)/OCD Clinic, a
multidisciplinary specialty clinic at the Yale Child Study Center. Eligible participants
were required to (1) have a childhood diagnosis of OCD, (2) have participated in
magnetic resonance imaging or neuropsychological testing studies prior to 16 years of
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age (these were prerequisites for having a detailed clinical research evaluation at that
time), and (3) be older than 16 years at the time of potential follow-up interview. Early
adulthood follow-up interview took place an average of 9 years after the initial childhood
evaluation. Exclusionary criteria included a history of seizure, head trauma with loss of
consciousness, ongoing or past substance abuse, or an IQ lower than 80. Parental written
informed consent and subject assent were performed at childhood baseline assessment,
and subject informed consent was performed at follow-up. Compensation for
participation was provided at both time points under the guidelines of the Yale Human
Investigations Committee.
From an eligible sample of 62 subjects evaluated at the baseline interview, 46
(74%) elected to participate. Reasons for nonparticipation included subject refusal to
participate in a follow-up interview (n = 2) or inability to locate subjects (n = 14). At the
follow-up interview, it was found that one participant had since been diagnosed with
Asperger’s disorder. He and his mother were re-interviewed by an expert clinician (Dr.
Michael Bloch), and it was determined that he met criteria for Asperger’s disorder rather
than OCD in childhood, and he was therefore excluded from subsequent analyses.
Demographic data as assessed at childhood baseline did not differ significantly between
participants and non-participants, except for age at baseline evaluation (Table 1).
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TABLE 1:
Demographic
N
Age at Evaluation*
Gender (N, % male)
TS
ADHD
CY-BOCS
YGTSS

Participants
45
12.1 ± 2.1
37 (82%)
18 (40%)
18 (40%)
11.6 ± 8.1
8.0 ± 10.8

Non-Participants
16
9.9 ± 1.6
12 (75%)
11 (69%)
6 (38%)
14.2 ± 9.8
14.2 ± 10.8

TABLE 1. Demographic Comparison of Participants and Non-participants. Participants
differed significantly from non-participants only in that non-participants were younger at
the baseline evaluation than non-participants. *= p<0.001
Interview Procedure at Childhood Baseline Assessment
Childhood baseline assessment occurred prior to age 16 years and included current and
worst-ever measures of obsessive-compulsive (OC) symptom severity using the
Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS), a widely-used and
well-validated instrument that rates symptom severity on the basis of time spent, distress,
and impairment (89). The Yale Global Tic Severity Scale (YGTSS) was used to assess
current and worst-ever tic severity (90). The Schedule for Tourette and Other Behavioral
Syndromes was used to survey other psychiatric illnesses (91). Neuropsychiatric
diagnoses were established through a best-estimate consensus procedure performed by
two child psychiatrists (Drs. Bradley Peterson and James Leckman) following a review of
all available materials (92). Participants were then classified based on these diagnoses on
their diagnosis status (yes/no) for Tourette syndrome (TS), chronic tic disorder (CTD),
Attention-Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder
(depression), comorbid anxiety disorder other than OCD (anxiety), and Oppositional
Defiant Disorder (ODD). Participants and their families were also asked about the
participant’s age of onset of OC symptoms.
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Interview Procedure at Early Adulthood Follow-Up
Evaluations during follow-up in early adulthood included current and worst-ever ratings
on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and YGTSS (90, 93).
Screening for comorbid psychiatric conditions was conducted with the Structured
Clinical Interview for DSM-IV Axis I Disorders, and a standardized medication history
was obtained (94). In addition, an interview of a parent or “close cohabitating adult” was
performed to verify symptom severity when possible. All subjects who had improved
significantly were also asked to provide the age at which their OC symptoms “remitted,”
which was defined in the interview as the age that “the age your OC symptoms improved
substantially.”

DATA ANALYSIS
All statistical analyses were performed using SAS version 9.1. The primary outcome
variable for analysis was time to remission of OC symptoms from the initial childhood
assessment. A participant was considered remitted if the Y-BOCS< 8 at follow-up. A YBOCS score of <8 was chosen as criteria for remission because the anchor point of 8
demarcates subclinical (YBOCS 0-7) from clinical OC symptoms (YBOCS≥8) (93). Age
of OCD remission was determined by patient self-report at follow-up, and time to
remission was calculated by subtracting age of baseline childhood assessment from age
of remission.
The Kaplan-Meier method (implemented with SAS proc lifetest) was used to plot
the overall survival function of the data and to test whether the a priori childhood clinical
variables influenced the overall survival curve. Subjects were stratified by comorbid
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CTD and by primary OCD symptom dimension (Symmetry, Cleaning, Forbidden
thoughts, or Hoarding). The Wilcoxon test was used to compare survival curves, as this
method places greater weight on time points that are associated with more observations.
Bonferroni correction was used to set the threshold for statistical significance at p<0.025
to account for the two a priori hypotheses.
The Cox Proportional Hazards model of survival analysis (proc phreg command
in SAS) was then employed to construct the best fitting exploratory model of the data. In
the model the following variables of interest were examined: age of onset, OCD severity
at baseline childhood assessment, age at baseline assessment, depression, anxiety, TS,
CTD, ADHD, conduct disorder, ODD, gender, and worst-ever OCD severity. The best
fitting model was built using the following steps: (1) all univariate variables that were
significantly associated with time to OCD remission were identified, (2) all significant
univariate terms were entered into the same model, and individual terms were identified
based on the least significant p-value and then removed if they did not significantly
improve the fit of the model based on Log-Likelihood Test, and (3) all non-significant
univariate predictors of time to remission were added back into the model and kept if
they improved fit of the model based on the Log-Likelihood Test (with a p<0.05
threshold). The dimensional measures of OCD were then added to the best fitting model
with traditional clinical data to determine if this approach improved fit of the model.
Dimensional OC symptoms were measured using factor scores for OCD dimensions
computed in a previously published study; OC symptoms in each dimension were rated
as 0=absent, 1=present, or 2=severe; and participants were categorized as primarily
having hoarding symptoms or not. These dimensional approaches were only included in
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the final best fitting model if they improved the goodness of fit based on the LogLikelihood Test.
In post hoc analysis baseline characteristics of subjects classified as remitters
were compared to non-remitters at early adulthood follow-up. All continuous variables
were examined using a student t-test and categorical variables with the Fisher’s exact test.

RESULTS
Childhood baseline interview took place at an average age of 12.1 ± 2.0 years (range 8.0 15.8). Additional demographic characteristics are provided in Table 1. The average age
at early adulthood follow-up was 21.1 ± 3.1 years (range 16.0 – 27.0). The average
duration between initial and follow-up interviews was 9.0 ± 2.9 years.

Clinical Course of Obsessive-Compulsive Symptoms
The average age of onset of OC symptoms was 8.0 ± 2.5 years (range 4-13). At followup, the average Y-BOCS score was 10.2 ± 8.6 compared to 25.6 ± 7.1 at worst-ever (age
11.3 ± 2.4 years). Twenty subjects (44%) had minimal OC symptoms at follow-up and
were classified as remitted (Y-BOCS <8) (Table 2). Fourteen subjects (31%) had mild
OC symptoms (Y-BOCS score 8-15) at follow-up, while 6 subjects (13%) had moderate
OCD (Y-BOCS score 16-23), and 5 subjects (11%) had severe OC symptoms (Y-BOCS
score 24-40).
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Remitting Participants Compared to Non-Remitting Participants
Table 2 compares the characteristics of children whose OC symptoms remitted by the
time of the early adult assessment to those who did not. Lesser OCD severity at
childhood assessment, presence of a comorbid tic disorder, and absence of hoarding
symptoms were associated with remission in adulthood. Male gender and lesser worstever childhood OCD severity were associated with OCD remission at trend levels.
TABLE 2:
Demographic
Age at Childhood Baseline
Gender -- males^
Age of Onset
Duration of Symptoms
OCD Severity at Childhood Assessment*
Worst-Ever Childhood OCD Severity^
Comorbid Conditions
Tourette Syndrome
Chronic Tic Disorder*
Attention-Deficit Hyperactivity Disorder
Depression
Oppositional Defiant Disorder
Primary OCD Symptom Dimension
Cleaning
Forbidden Thoughts
Symmetry
Hoarding*
Medication Use
Childhood Baseline Assessment
Serotonin Reuptake Inhibitors
Antipsychotics
Alpha2-agonists
Adulthood Follow-up Assessment
Serotonin Reuptake Inhibitors
Antipsychotics
Alpha2-agonists

Remitted
(N=20)
12.1 +/- 2.1
18 (90%)
7.6 +/- 2.5
4.5 +/- 2.1
8.4 +/- 4.7
23.7 +/- 8.4

Non-Remitted
(N=24)
12.1 +/- 2.1
16 (67%)
8.4 +/- 2.6
3.7 +/- 3.5
14.3 +/- 9.4
27.8 +/- 6.0

10 (50%)
16 (80%)
10 (50%)
6 (30%)
6 (30%)

7 (29%)
10 (42%)
8 (33%)
7 (29%)
7 (29%)

7 (35%)
6 (30%)
6 (30%)
1 (5%)

5 (21%)
5 (21%)
5 (21%)
9 (38%)

19 (95%)
11 (55%)
7 (35%)

22 (92%)
12 (50%)
6 (25%)

11 (55%)
3 (15%)
1 (5%)

16 (67%)
4 (17%)
1 (4%)

TABLE 2. Characteristics of Remitting and Non-remitting Participants. Participants
whose OC symptoms remitted in adulthood were less likely to have primary hoarding
symptoms and more likely to have a comorbid chronic tic disorder when compared to
non-remitters. *=p<0.05 and ^=p<0.1. Table courtesy of Dr. Michael Bloch.
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Severity and Timing of Worst-Ever Obsessive-Compulsive Symptoms
The mean worst-ever Y-BOCS score was 25.6 ± 7.1, which occurred at a mean age of
11.3 ± 2.4 years. For the majority of the participants (N = 30; 66.7%), the timing of their
worst-ever OC symptoms occurred prior to their evaluation at childhood baseline
assessment. Figure 1 presents a box plot showing the progression of OC symptom
severity at worst-ever, childhood baseline assessment, and follow-up.

FIGURE 1:

CY-BOCS / Y-BOCS Score
Time

Figure 1. Box plot showing progression of OC symptom severity over time. Time is
represented on the x-axis and CY-BOCS or Y-BOCS score is represented on the y-axis.
Plot displays Y-BOCS score at the worst-ever time period, CY-BOCS score at time of the
initial assessment in childhood, and Y-BOCS score at follow-up in early adulthood.
Worst-ever severity is depicted first, as the majority of participants experienced their
peak severity of symptoms prior to the baseline evaluation.
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Comorbid Conditions at Follow-Up
At the time of the follow-up interview, 13 participants (29%) had a history of major
depressive disorder, while two participants (4%) currently met criteria for major
depression. One participant had been diagnosed with a psychotic disorder and another
with bipolar disorder during the follow-up interval. No subjects had bipolar disorder or
psychotic symptoms at the childhood assessment. Seven participants (16%) met criteria
for alcohol abuse, three of whom also met criteria for substance abuse. Two additional
subjects were using substances in the absence of alcohol abuse, making five (11%) the
total number of participants who met criteria for substance abuse at follow-up.

Medication Use at Follow-Up
At the baseline childhood evaluation, 41 participants (91%) were taking selective
serotonin reuptake inhibitors (SSRIs). At follow-up, 27 (60%) patients continued to take
SSRIs, while 14 (31%) patients had stopped using them. Only four participants (9%) had
never used SSRIs. Two subjects (4%) were using alpha2-agonists at adulthood followup, compared to 9 (20%) at childhood baseline evaluation. Seven participants (16%)
were taking antipsychotic medications at adulthood follow-up as compared to 22 subjects
(49%) who were taking them at childhood evaluation. There were no significant
differences between remitted and non-remitted OCD subjects in terms of medication use
at the time of the baseline childhood evaluation or at the adulthood follow-up.
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Kaplan-Meier Model for A Priori Predictors of Time to OCD Remission
Kaplan-Meier survival plots demonstrated a reduced time to remission of OC symptoms
for subjects with comorbid tic disorders (χ2=6.0, df=1, p=0.02) (Figure 2). Primary OCD
symptom dimension was also associated with likelihood of remission at trend levels
(χ2=6.6, df=3, p=0.09) (Figure 3). This result appeared to be primarily due to a
significantly decreased likelihood of remission among individuals with primary hoarding
symptoms compared to other children with OCD and primary symptoms in other
dimensions (χ2=5.4, df=1, p=0.02).
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FIGURE 2:

Proportion of Individuals with Clinically Significant OCD
Years Since OCD Diagnosis in Childhood

Figure 2: Survival curve comparing patients with OCD with and without comorbid
chronic tic disorders. (Comorbid chronic tic disorder (red) and without (black); circles
represent censored observations). Proportion of patients whose OCD remitted is
displayed on the y-axis and time since childhood baseline assessment is displayed on the
x-axis. Patients with a comorbid chronic tic disorder experienced a decreased time to
remission of OC symptoms (χ2=6.0, df=1, p=0.02). Figure courtesy of Dr. Michael
Bloch.
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FIGURE 3:
Proportion of Individuals with Clinically Significant OCD
Years Since OCD Diagnosis in Childhood

Figure 3. Survival curve comparing patients by primary symptom dimension. (Symmetry
(red), Cleaning (green), Forbidden thoughts (black) and Hoarding (blue), circles represent
censored observations). Proportion of patients with OCD who remitted is displayed on
the y-axis and time since childhood baseline assessment is displayed on the x-axis. OCD
symptom dimensions were associated with differences in likelihood of remission at trend
levels (χ2=6.6, df=3, p=0.09). Primary hoarding symptoms were associated with a
significantly decreased likelihood of remission (χ2=5.4, df=1, p=0.02) compared to nonhoarding OCD symptoms. Figure courtesy of Dr. Michael Bloch.
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Cox-Proportional Hazard Model for Time to OCD Remission
The best fitting model by the Likelihood Ratio test is depicted in Table 3. Female
gender, absence of comorbid tic symptoms, more severe initial OC symptoms, younger
age at childhood assessment, older age of onset, comorbid ODD, and primary hoarding
symptoms were associated with increased time to remission of OCD symptoms. Using
patient factor scores for OCD symptom dimensions and classifying OCD severity in each
dimension did not improve the overall fit of our model compared to the clinical variables
alone (the best fitting model without the primary hoarding symptom variable).

TABLE 3:
Parameter
Gender (male=0, female=1)
Childhood CY-BOCS
Age at baseline assessment
Chronic Tic Disorder
ODD
Age of OCD onset
Primary Hoarding symptoms

HR
0.06
0.89
2.00
4.50
0.17
0.77
0.09

95% CI
0.02-0.15
0.85-0.94
1.64-2.43
2.15-9.42
0.08-0.35
0.70-0.84
0.03-0.25

p
0.002
0.018
<0.001
0.042
0.014
0.004
0.023

TABLE 3. Cox-Proportional Hazards Model of Time to Remission of Pediatric-Onset
OC symptoms. A lower hazard ratio indicates an increased time to remission of OC
symptoms. Female gender, more severe initial OC symptoms, younger age at initial
assessment, later age of onset, comorbid ODD, absence of comorbid tic symptoms and
primary hoarding symptoms were associated with increased time to remission. Overall
model fit statistics: Likelihood Ratio χ2=38.0, df=7, p<0.0001. Abbreviations:
HR=hazard ratio, CY-BOCS=children’s Yale-Brown Obsessive-Compulsive Scale,
ODD=Oppositional Defiant Disorder, OCD=Obsessive-Compulsive Disorder. Table
courtesy of Dr. Michael Bloch.

31
DISCUSSION
The results of this follow-up study examining the early adult outcome of patients with
pediatric-onset OCD indicate that a significant proportion of children with OCD will
remit by early adulthood. Depending on the criteria used for OCD remission, the
percentage of children who remitted ranged from 44% (Y-BOCS <8) to 58% (Y-BOCS
<10). This result is remarkably consistent with the results of a recent meta-analysis of
previous studies of pediatric-onset OCD that reported rates of remission between 40-59%
(75), but it is in stark contrast to outcome studies of adults, which report significantly
lower rates of remission (95). The results also provide valuable information regarding
the course and progression of pediatric-onset OCD.
In this study, children with OCD and chronic tic disorder had a decreased time to
remission of OC symptoms when compared to participants without tics – 62% of patients
with pediatric-onset OCD and tics remitted by early adulthood, whereas only 22% of
patients without a tic disorder remitted (Table 2). This finding goes against our
hypothesis that the presence of tics would be associated with persistence of OC
symptoms into early adulthood. It is also in contrast to the results of other longitudinal
studies of OCD, which have demonstrated that the presence of tics is associated with
increased OCD severity at follow-up (73, 74). One reason for this discrepancy may be
that a larger proportion of participants in this study had tics when compared to other
study populations.
When compared to patients with OCD without tics, patients with OCD and tics
have been shown to have a comparable response to cognitive behavioral therapy but a
worse short-term response to sertraline treatment (42), as well as a more favorable
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response to antipsychotic augmentation (43). In studies of the course of tics in patients
with Tourette Syndrome, tic symptoms typically reach their peak severity between 10-12
years of age and then improve during the course of adolescence (96, 97). The
developmental changes that are responsible for improving tics in children during the
adolescent years may also help to ameliorate OC symptoms in these children.
Participants with primary hoarding symptoms appeared to have a poorer longterm outcome when compared with other children with OCD whose primary symptoms
were within other dimensions – rates of remission were 10% and 54%, respectively.
Some experts have suggested that the Hoarding symptom dimension should be used as a
specifier in the next version of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-V), and a strong case can be made that compulsive hoarding in the
absence of OCD should be listed as a separate diagnostic entity (98, 99). Results from
several studies suggest that patients with OCD and primary hoarding symptoms are
different from those without hoarding symptoms. As compared to patients with OCD
without hoarding symptoms, patients who exhibit hoarding behavior have been reported
to display more severe obsessions and compulsions (93), have a higher prevalence of
comorbid personality disorders (100-102), and respond less favorably to SSRIs and
cognitive-behavioral therapy (56, 58, 59, 103). In addition, neuroimaging studies have
demonstrated differences in glucose metabolism, brain activation patterns (104, 105), and
grey matter (106) among patients with compulsive hoarding symptoms when compared
to other patients with OCD. The results of a recent genetic study suggest that a region on
chromosome 14 is linked with compulsive hoarding behavior in families with OCD
(107). These data suggest that patients with OCD and compulsive hoarding symptoms
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are clinically and perhaps etiologically different from those without hoarding behavior
and may indeed represent a distinct subtype of the disorder.
The results of multivariate, exploratory survival analyses demonstrated that
increased OCD severity at baseline was associated with longer time to remission. Given
that a Y-BOCS score of less than 8 was required to meet criteria for remission, this is not
especially surprising since patients with more severe OCD would need a greater degree
of improvement to achieve this metric. Initial severity of OCD has been reported to
predict increased severity at follow-up in some but not all longitudinal studies of
pediatric-onset OCD (75). A later age of onset and younger age at baseline evaluation
were also found to be associated with increased time to remission of OC symptoms. This
result is in contrast to those of previous long-term outcome studies that have
demonstrated that earlier age of onset and increased duration of illness are associated
with greater OCD persistence (75). The longer interval between baseline evaluation and
follow-up, higher proportion of participants with comorbid tic disorders, and the use of
multivariate as opposed to univariate analysis may in part explain this difference.
Comorbid ODD was also associated with poorer long-term prognosis. While there are
little data examining the relationship between OCD and comorbid ODD, other comorbid
externalizing disorders such as ADHD have been associated with increased functional
impairment among children with OCD (108).
Finally, female gender was associated with increased time to remission of OC
symptoms. While there are little data available regarding gender differences in OCD, it
has been suggested that gender may provide useful insight into the clinical and biological
heterogeneity of the disorder (109). Some studies have demonstrated differences in
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symptomatology, with females exhibiting more washing rituals and contamination fears
(110, 111) and males displaying more checking and symmetry compulsions (111).
Comorbidity studies have demonstrated increased prevalence of eating disorders (112)
and depression (112, 113) among females with OCD, while investigations of the role of
gender in genetic studies of OCD have yielded mixed results (109). In selected previous
follow-up studies of pediatric-onset OCD female gender has predicted an episodic course
(74, 114), while male gender was predictive of a more chronic course (74). Future
studies of long-term outcome in pediatric-onset OCD will be necessary to elucidate the
role of gender in the disorder.
This study has several limitations. First, the participation rate for all eligible
participants in the follow-up portion of the study was 74%. While the only significant
demographic difference between participants and non-participants was age at baseline
assessment, it is possible that there were other systematic differences between the groups
that would have emerged at the follow-up interview. In addition, the study relied on
retrospective reporting of age of remission. Because multiple clinical and dimensional
variables were tested in the multivariate Cox survival models, there exists a higher
likelihood for Type I error, and therefore findings from these models should be regarded
as hypothesis-generating. Further studies will be necessary to confirm these results.
Finally, participants underwent treatment with both pharmacological and cognitivebehavioral therapies throughout the interval between baseline assessment and follow-up,
so the outcomes and predictor variables identified are indicative of the clinical course of
OCD rather than its natural history.
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Despite these limitations, this study provides important data regarding the course
and early adulthood outcome of pediatric-onset OCD. It substantiates the results of
previous longitudinal studies that suggest that a majority of patients who experience onset
of OCD in childhood will remit by the time they have reached early adulthood. Further,
it provides information regarding the course of OC symptoms - in this group of patients,
most children experienced an onset of symptoms around 8 years of age and most severe
symptoms around 11 years. This information will be especially important for children
and families who are receiving a new diagnosis of OCD and are interested in what to
anticipate in terms of course and prognosis. Given that OCD can be significantly
debilitating, clinicians, patients, and families will likely welcome the degree of optimism
that comes with these results.
In this study comorbid tics were associated with improved long-term outcome in
pediatric-onset OCD, suggesting that the presence of tics may indicate a clinical course of
OCD that follows a trajectory similar to that of Tourette Syndrome, in which symptoms
are more likely to remit during adolescence. In addition, this study identified subgroups
of patients, particularly those with primary hoarding symptoms, that may have worse
outcomes than other patients with OCD. This finding contributes to the growing body of
evidence in support of a multidimensional model of OCD and suggests that compulsive
hoarding may represent a discrete clinical entity. Moreover, it underscores the
importance of early characterization of symptoms and comorbidities in patients with
pediatric-onset OCD in order to identify patients at higher risk. It also emphasizes the
need for development of improved pharmacological and cognitive-behavioral therapies
for children, especially for those who display compulsive hoarding symptoms.
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